The Drugs (Eighth Amendment) Rules, 2026, notified by the Ministry of Health and Family Welfare on 29 June 2026, amend the Drugs Rules, 1945 to bring cell or stem cell-derived products, gene therapeutic products and xenografts under the Centrally License Approving Authority (CLAA) framework.
Under CLAA, manufacturing licences for these products are issued under the joint supervision of the Central Licensing Authority and the State Licensing Authorities, giving one uniform standard nationwide.
CLAA earlier covered critical biologicals such as vaccines, large volume parenterals (IV fluids above 100 ml) and recombinant-DNA medicines.
Products now covered include CAR-T cell therapy for blood cancers, gene replacement and gene-editing therapies, and animal-derived heart valves used in cardiology.
Parent law regulating import, manufacture, distribution and sale of drugs and cosmetics; empowers the Centre to frame rules.
Licensing, inspection, testing, labelling and quality-control procedures; amended here to widen the CLAA list.
Treat stem cell-derived products, gene therapeutic products and xenografts as 'new drugs' for trial and marketing approval; the 2026 amendment tightens the manufacturing-licence side.
| Category | What it is | Example use |
|---|---|---|
| Cell / stem cell-derived products | Therapies made from living cells, including engineered immune cells | CAR-T therapy for leukaemia and lymphoma; regenerative therapies |
| Gene therapeutic products | Products that replace, add or edit genes | Genetic disorders and some cancers |
| Xenografts | Tissue or organs transplanted from another species | Animal-derived heart valves in cardiology; orthopaedics |
National drug regulator under the Directorate General of Health Services, MoHFW; headed by the Drugs Controller General of India, who is the Central Licensing Authority
State drug controllers who license manufacture and sale; share oversight with the Centre under CLAA
Notified the amendment
A patient's own T-cells are extracted, engineered to carry a chimeric antigen receptor (CAR) that recognises a cancer marker, multiplied and re-infused to hunt cancer cells. India's first indigenous CAR-T, NexCAR19, was developed by ImmunoACT (IIT Bombay-Tata Memorial) and approved by CDSCO in 2023.
Simple Analogy: Giving the body's guard dogs the scent of the intruder.
GS Paper II > Health — regulation; GS Paper III > Biotechnology
General Awareness > Acts and regulators; General Science > Biotechnology
General Awareness > Government notifications
Centrally License Approving Authority — central approval of state-issued licences for specified high-risk products.
Graft of tissue or organ from one species into another.
Treating disease by replacing, inactivating or editing genes.
Injectable fluids above 100 ml, such as IV solutions.